Active, not recruitingPhase 2NCT04579380
Basket Study of Tucatinib and Trastuzumab in Solid Tumors With HER2 Alterations
Studying Rare tumor of gallbladder and extrahepatic biliary tract
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Seagen, a wholly owned subsidiary of Pfizer
- Principal Investigator
- Pfizer CT.gov Call CenterPfizer
- Intervention
- tucatinib(drug)
- Enrollment
- 217 enrolled
- Eligibility
- 18 years · All sexes
- Timeline
- 2021 – 2026
Study locations (30)
- HonorHealth, Phoenix, Arizona, United States
- HonorHealth, Tempe, Arizona, United States
- The University of Arizona Cancer Center-North Campus, Tucson, Arizona, United States
- City of Hope at Huntington Beach, Huntington Beach, California, United States
- City of Hope at Irvine Sand Canyon, Irvine, California, United States
- Koman Family Outpatient Pavilion, La Jolla, California, United States
- UC San Diego Medical Center - La Jolla (Jacobs Medical Center / Thornton Pavilion), La Jolla, California, United States
- UC San Diego Moores Cancer Center- Investigational Drug Services, La Jolla, California, United States
- UC San Diego Moores Cancer Center, La Jolla, California, United States
- City of Hope at Long Beach Worsham, Long Beach, California, United States
- City of Hope at Long Beach Elm, Long Beach, California, United States
- City of Hope at Newport Beach Lido, Newport Beach, California, United States
- City of Hope Torrance, Torrance, California, United States
- Rocky Mountain Cancer Centers, Aurora, Colorado, United States
- Rocky Mountain Cancer Centers, Boulder, Colorado, United States
- +15 more locations on ClinicalTrials.gov
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT04579380 on ClinicalTrials.gov